🇺🇸

US SEC Filing Intelligence

· daily

S&P 500 Healthcare Sector SEC Filings — March 24, 2026

Across the USA S&P 500 Healthcare stream's 36 filings, biotech and medtech firms dominate with mixed sentiment: clinical advancements and FDA milestones offset widening net losses (avg +25% YoY across Achieve, Absci, Artelo) driven by 25-40% YoY op ex surges amid flat/declining revenues. S&P 500 heavyweights like Medtronic, Centene, and Thermo Fisher show strategic progress—FDA clearance, leadership promotions, and M&A completion—but face short-term EPS dilution and charges. Cash positions strengthened via financings (e.g., Absci $144M to H1 2028, Achieve $36M up 6% YoY), supporting runways through 2027-2028, while capital allocation leans toward R&D reinvestment over dividends/buybacks. Key portfolio trends: 4/7 core healthcare cos reported loss expansion despite asset growth (avg +5% YoY), with H1-H2 2026 catalysts clustering around PDUFAs, trial data, and launches. Non-health filings (e.g., mortgage trusts, FHLBs) neutral, highlighting compliance and debt issuance but irrelevant to sector. Implications: tactical longs on catalysts, hedge burn risks; relative outperformance in clinical progress vs. financial deterioration.

20 high priority 16 medium 36 total filings
· daily

US Executive Compensation Proxy SEC Filings — March 24, 2026

Across 42 DEF 14A proxy statements filed on March 24, 2026, a dominant theme is robust 2025 financial performance in energy, materials, and insurance sectors, with 12/42 filings highlighting YoY growth in key metrics like production (Magnolia +11%), net income (Nicolet +22%, Hamilton $576.7M), and cash flow (Albemarle OCF +86%, Eastman $1B). Capital allocation trends show strong shareholder returns, including $1.9B repurchases at Arch, 75% FCF returned at Magnolia ($322M total), and Vulcan's $700M dividends/buybacks, amid 16th consecutive dividend raise at Eastman. Mixed signals emerge in logistics (CH Robinson revenues -8.4% YoY but EPS +25.1%; Expeditors ocean decline), while governance focuses on say-on-pay votes (all recommending approval) and director elections cluster in May 2026. Notable M&A includes American Water's $3.7B capex and Essential Utilities acquisition by Q1 2027 end, plus Albemarle's $670M divestitures closing March 2026. Portfolio-level, 18/42 filings report positive YoY trends (avg revenue/sales growth ~10% where disclosed), signaling sector rotation into resources; risks center on delistings (BNB PLUS) and reorgs (Digimarc). Upcoming virtual annual meetings (35+ in April-May 2026) serve as catalysts for comp alignment and governance votes, with neutral sentiment in 60% but positive in high-materiality resource names.

42 high priority 42 total filings
· daily

US IPO Pipeline SEC S-1 Filings — March 24, 2026

Four S-1 filings on March 24, 2026, underscore a diverse IPO pipeline: a new SPAC (Research Alliance Corp III), post-IPO amendment for Forgent Power Solutions (IPO closed Feb 6), proposed IPO for Arxis, and resale registration for biotech Artelo Biosciences amid distress signals. Overarching themes include standard SPAC protections, acquisition-driven asset buildup in power sector (FPS intangibles from PwrQ/States/VanTran/MGM), extensive regulatory/compliance risks (Arxis FCPA/ITAR/FAA), and dilution/Nasdaq pressures (Artelo 1-for-3 reverse split reducing shares 65% from 2.12M to 736K). No uniform period-over-period trends across filings, but FPS flags Q4 2025 customer concentration risk in revenue/accounts receivable, contrasting neutral sentiment in SPAC/FPS vs negative in Arxis and mixed in Artelo. Critical developments like FPS over-allotment options (Feb 9) and Artelo Nasdaq extension to March 30 imply near-term catalysts, with high materiality (9-10/10) signaling investor attention. Portfolio-level pattern: 75% neutral/mixed sentiment suggests resilient IPO momentum despite biotech distress, positioning SPACs/power plays for alpha amid aerospace/biotech hurdles.

4 high priority 4 total filings
· daily

Global High-Priority Regulatory Events — March 24, 2026

Across 50 filings in the Global High Priority Market Events stream, dominant themes include ongoing insolvency proceedings in 6+ Indian firms (e.g., Future Lifestyle, Punj Lloyd, Unitech International), signaling distress in retail, pharma, and construction sectors; multiple open offers/takeovers (Rekvina Labs, Photon Capital, Aar Shyam) indicating consolidation plays; and widespread trading window closures starting April 1, 2026, ahead of Q4/FY2026 earnings for energy/refinery firms like MRPL, Godavari, Jagsonpal. US-centric 10-K/20-F reports show mixed financials: revenue surges (FTC Solar +110.5% YoY to $99.7M, Audax portfolio +46% to $949.8M) offset by widening losses or going concern doubts (Vertical Aerospace operating loss +108% to £127M, Ocean Thermal net loss $69.3M), while capital returns shine with TVS Motor's ₹570 Cr dividend (₹12/share) and Arch Capital's $1.9B buybacks. Period-over-period trends reveal improving gross margins (FTC Solar -0.9% vs -26.6% prior) but rising op expenses/R&D in tech/energy (Vertical R&D +20% YoY); insider policies strict but no transaction data signals conviction shifts. Portfolio-level, 7/15 annual reports show revenue growth averaging +45% YoY but net losses in 9/15 (avg widening 20-100%), with M&A/amalgamations (Torrent-JB Chemicals) and ATM facilities (Aardvark $150M) as catalysts. Implications: monitor Indian insolvencies for distress alpha, US solar/energy for turnaround bets, and earnings catalysts mid-April-May for volatility.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — March 24, 2026

Across 50 filings dated March 24, 2026, primarily FY2025 10-Ks, sentiment is predominantly mixed (24/50) or neutral (18/50), with operating companies showing divergent trends: explosive revenue growth in solar (FTC Solar +110.5% YoY) and AI/hardware (Blaize +2,387% YoY) contrasted by widening net losses in biotechs (e.g., COMPASS +85.6%, Fractyl +105%, Neurogene +20.2%) and sharp declines in energy trusts (VOC -37% income, MV Oil -39%). Retail outliers like GameStop delivered +218.7% net income surge despite -5.1% sales drop via margin expansion (+7.4 pts to 33%), while 25+ ABS/mortgage trusts reported routine Reg AB compliance with no material issues, signaling stable structured finance servicing. Portfolio-level trends reveal biotech cash burn averaging +30% YoY (e.g., Achieve +37%, Neurogene +9.4%), energy reserve/production declines (4-11% YoY), and modest infra growth (Core & Main +2.8% sales). Capital allocation leans toward financing inflows for cash preservation (e.g., FTC +$40.4M), but no broad insider patterns noted; implications favor selective longs in margin improvers amid biotech/energy caution, with ABS neutrality supporting fixed-income stability.

50 high priority 50 total filings
· daily

US SEC Trading Suspension Halt Orders — March 24, 2026

Both BNB Plus Corp. and SurgePays, Inc. disclosed Nasdaq notifications for failing minimum listing standards, signaling acute delisting risks on the Nasdaq Capital Market amid chronically low bid prices below $1.00. BNB Plus is ineligible for a standard compliance period due to prior reverse stock splits totaling a 250:1 ratio over the past two years, while SurgePays has 180 calendar days to cure MVLS ($35M) and bid price deficiencies but faces immediate dilution from issuing 800,000 shares to CEO Brian Cox at $1.25/share to settle a $1M promissory note. No positive period-over-period financial trends evident; implied QoQ stock price deterioration with BNBX bid < $1 for 30 consecutive days (Feb 5-Mar 19, 2026) and SurgePays similarly deficient. Cross-filing pattern reveals 2/2 companies at Materiality 9/10 negative sentiment, highlighting systemic small-cap distress on Nasdaq. Forward-looking catalysts include BNB's planned hearing request and SurgePays' compliance deadlines in September 2026, but no assurance of listing retention. Portfolio-level implication: Heightened volatility and liquidity risks for Nasdaq small caps, urging avoidance or short strategies.

2 high priority 2 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — March 24, 2026

In the USA Corporate Distress & Bankruptcy intelligence stream spanning 40 filings (28 new), overarching themes reveal acute liquidity pressures with 12 companies securing covenant waivers/amendments (e.g., FTC Solar waiving purchase order breach, Southland assigning $110M loans), 4 facing Nasdaq delisting risks (BNB PLUS, SurgePays, Hub Group delay, implied others), and one outright restructuring (Cannabist CCAA/Chapter 15 with asset sales). No uniform period-over-period declines in revenue/EBITDA, but distress signals include covenant breaches (FTC Solar Q4 2025), delayed 10-Ks (Hub Group restating Q1-Q3 2025), and high-cost financings (NightFood 15% OID note). Positive offsets: 8 new/expanded facilities (Aardvark $150M ATM, Portland GE $350M term loan, Innodata $50M credit), asset sales for debt paydown (Krispy Kreme $160M total, CVD $16.9M), and buybacks (Robinhood $1.5B). Portfolio trends show small-cap biotechs/construction with 70% mixed/negative sentiment vs. energy/finance at 40%; margin trends N/A but EBITDA covenants tightened (FTC Solar $10M min 2026). Critical implications: Elevated bankruptcy risk in cannabis (Cannabist) and solar (FTC Solar stringent ramps); turnaround alpha in refranchising (Krispy) and refinancings (Moog extending 7 years). Actionable now: Avoid delisting candidates, monitor Q2 2026 catalysts.

40 high priority 40 total filings
· daily

US Executive Officer Management Changes SEC — March 24, 2026

Across 37 filings on USA executive and director changes dated March 24, 2026, a dominant theme is CFO turnover, with 10+ cases including a cluster of 6 New Mountain entities (e.g., Guardian IV BDC, Finance Corp) where Kris Corbett resigned as CFO effective post-transition by May 29, 2026, signaling potential short-term reporting risks but no disagreements noted. Positive internal promotions and experienced external hires dominate (e.g., Rush Enterprises COO, Dollar General CEO succession, Twilio/eBay board adds), reflecting proactive leadership refreshes amid sector growth, while high-materiality shocks like Simon Property Group CEO David Simon's death (10/10 materiality) and Indaptus Therapeutics' 96% change of control highlight acute vulnerabilities. Velo3D stands out with enriched financials: FY2025 revenue +12% YoY to $46M but gross margins cratered to -16.1% from -5.1% due to $7M write-downs, offset by $60-70M 2026 guidance and cash build to $39M (+3,150% YoY). Portfolio-level trends show neutral-to-positive sentiment in 70% of filings, with board expansions (e.g., Camp4, eBay) and retention incentives (e.g., Brag House RSUs replacing options) indicating management conviction; however, disputed CFO exits (FOXO) and planned retirements (Chesapeake, Solventum) cluster in finance/utilities. Implications: Investors should prioritize smooth successions for alpha (e.g., retail/tech) while monitoring BDC/fintech transition risks for volatility. No broad margin compression but isolated deteriorations (Velo3D -1,135 bps QoQ Q4); capital allocation leans toward equity incentives over buybacks/dividends.

37 high priority 37 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — March 24, 2026

The USA Bankruptcy & Insolvency stream features a single high-materiality (10/10) filing from Cannabist Co Holdings Inc., signaling acute distress in the cannabis sector with initiation of CCAA proceedings in Canada and planned Chapter 15 in the US to enable asset sales and orderly wind-down. Operations have ceased in New York and are ceasing in Pennsylvania, amid persistent operational challenges, with trading halt and delisting review imminent. Key asset divestitures include a closed $130M Virginia sale, pending $16.5M Delaware cash deal (Q2 2026 close), $47M Ohio sale ($34.5M cash + $12.5M note, Q3 2026 close), and a non-binding MOU for remaining assets in six states. Supporting noteholders (>60% of 9.25% Senior Secured Notes due 2028 and 9.0% Convertible Notes due 2028) endorse transactions, providing some creditor backing but underscoring equity wipeout risk. No period-over-period financial trends available, but operational contractions highlight deteriorating performance. Market implications include zero equity value potential, distressed asset opportunities, and broader cannabis sector contagion risks.

1 high priority 1 total filings
· daily

US Corporate Board Director Changes SEC Filings — March 24, 2026

Across 37 US SEC filings on boardroom changes dated March 24, 2026, a dominant theme is CFO and executive churn, particularly in private credit/BDC entities (New Mountain group: 13-15,17,18,20 with Kris Corbett resignations effective May 29, 2026), signaling potential leadership transitions amid sector pressures. Positive internal promotions and experienced external hires prevail in 70% of cases (e.g., RUSH, QuidelOrtho, eBay, Twilio, Dycom, American Airlines, Dollar General), boosting sentiment and stability in industrials, tech, and retail. Critical developments include Simon Property Group's CEO passing (materiality 10/10, mixed sentiment) with immediate family succession, Bitcoin Depot's CEO swap to fintech veteran Alex Holmes (9/10), and Indaptus Therapeutics' 96% control shift via $11.2M preferred stock sale (9/10 mixed). Portfolio-level trends show neutral/mixed sentiment in 45% of filings due to retirements/resignations without disputes, but no broad financial deterioration except Velo3D's FY2025 gross margins plunging to -16.1% from -5.1% YoY despite 12% revenue growth to $46M. Market implications favor monitoring fintech/retail for continuity premiums, while BDC/fund churn raises execution risks; overall, 18 positive appointments signal management deepening amid economic uncertainty.

37 high priority 37 total filings
· daily

US Merger & Acquisition SEC Filings — March 24, 2026

The 9 filings reveal a bifurcated US M&A landscape dominated by SPAC activity (6/9 filings), with progress via PIPE financings, non-redemption agreements, and administrative setups contrasting sharply against Oak Woods' imminent delisting for failing to complete a business combination within 36 months. Completed deals in operating companies show mixed pro forma impacts: LSI Industries' $325M acquisition boosts combined TTM revenue to $864M (+46% vs LSI standalone $593M) and EBITDA margin to 11% (from 9.7%), while Cardlytics' $25.4M divestiture narrows 2024 net losses 79% to $(40.4M) despite 8-9% revenue declines YoY. Playboy's JV sale secures $122M in contracted cash through 2033, enabling debt paydown and immediate earnings accretion. Period-over-period trends highlight profitability improvements post-transaction (e.g., Cardlytics net loss per share to $(1.72) in 2025) amid revenue softness, signaling portfolio-level deleveraging and strategic refocus. No insider trading or dividend/buyback changes noted across filings, but capital allocation leans toward debt reduction (Playboy) and acquisition funding via debt/equity (LSI). SPAC advancements build toward catalysts like S-4 filings and closings, while distress in one underscores sector risks.

9 high priority 9 total filings
· daily

US Merger & Acquisition SEC Filings — March 24, 2026

The 9 filings reveal robust M&A and takeover activity dominated by SPACs (6/9 filings) facing mixed fortunes, including PIPE financings, non-redemption support, administrative deals, but also delisting risks, alongside operating company divestitures and acquisitions showing pro forma financial improvements. Key period-over-period trends include revenue declines in divested units (Cardlytics: 2025 revenue down 9% pro forma to $212.3M) but narrower net losses (79% improvement in 2024 to $(40.4M)), EBITDA margin expansion via accretive deals (LSI: combined 11% from 9.7%), and secured future cash flows (Playboy: $122M contracted through 2033). Critical developments like LSI's $325M acquisition and Playboy's $15M JV sale signal strategic portfolio optimization, while SPAC challenges (Oak Woods delisting March 25, 2026) highlight deadline pressures post-36 months. Portfolio-level patterns show 3/9 with positive pro forma metrics (narrower losses, higher EBITDA), contrasting SPAC neutral/negative sentiment; sector themes point to industrials/licensing M&A strength amid SPAC fatigue. Implications favor monitoring post-deal integrations and SPAC closings for near-term catalysts, with asset-light shifts boosting returns.

9 high priority 9 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 24, 2026

Overnight SEC filings from March 23-24, 2026, reveal mixed financial momentum across US equities, with standout revenue accelerations in infrastructure (Smith-Midland Q4 +25% YoY to $22-24M, FY +18% to $92-94M) and solar (FTC Solar FY2025 +110.5% to $99.7M), offset by persistent net losses and operational pressures in 7/15 key 10-K/20-F reporters (e.g., Vertical Aerospace op loss +108% to £127M despite net profit swing). REITs and private credit funds shine with CareTrust REIT Normalized FFO +17% YoY to $1.76/share and record $1.764B cap deployment, Audax portfolio +46% to $949.8M, and Golub $10.2B portfolio at 1.33x leverage. Galaxy entities' 13F series disclose massive crypto/mining concentrations (e.g., $137.8B portfolio Q3 2025 with Core Scientific $19B), signaling bullish conviction amid volatility. Debt restructurings/waivers proliferate (FTC Solar $10M repayments, Inotiv liquidity waiver, Southland $110M assignment), raising liquidity flags in 5 firms, while capital returns persist via buybacks (News Corp $1B program, Flowco 780K shares) and dividends (Braemar prefs, Golub $0.1875/share). M&A speculation emerges (Estee Lauder/Puig talks), and proxies indicate governance stability (QXO/Intel annual meetings May). Portfolio-level trends: 6/10 high-materiality firms show YoY revenue growth averaging +65%, but margins mixed with gross improvements (FTC -0.9% vs -26.6%) amid covenant tightening; watch catalysts like WUTC rate approval Aug 1 and 10-K deadlines.

24 high priority 26 medium 50 total filings
· daily

Biotech Small-Cap Approvals — March 23, 2026

A cluster of five neutral FDA ANDA approvals for generic drugs (PALBOCICLIB, CLINDAMYCIN PHOSPHATE, DESOGESTREL, NINTEDANIB, CABOZANTINIB) occurred March 17-19, 2026, benefiting small-cap Asian sponsors (4/5 Indian/Chinese firms). All under standard review with no special designations or specified indications, signaling commoditized portfolio expansions rather than premium growth. Neutral implications dominate: modest operational wins offset by pricing pressures and limited visibility.

5 total filings
· daily

New Drug Approvals (Original) — March 23, 2026

FDA approved five neutral ANDA generics from March 17-19, 2026, all under standard review with no special designations or specified indications/therapeutic areas. Four approvals went to Indian sponsors (Natco, Aurobindo, Annora, Biocon) and one to China's Qilu, indicating routine portfolio expansions for emerging-market generic players. Three involve oncology drugs (PALBOCICLIB, NINTEDANIB, CABOZANTINIB), signaling modest competitive pressure in that sector without premium catalysts.

5 total filings
· daily

DHS Homeland Security Contracts — March 23, 2026

BCCG A Joint Venture secured three CBP delivery orders totaling $1.51B for border barrier construction in Weslaco, TX ($874M) and San Diego, CA ($639M combined), spanning 2025-2028 under full/open competition. This unprecedented concentration on one non-small JV signals strong DHS border security priorities and revenue backlog for NAICS 236220 contractors. Bullish for BCCG and sector peers, but $0 outlayed across awards flags near-term funding execution risks under firm-fixed pricing.

3 total filings
· daily

Federal Construction & Infrastructure Contracts — March 23, 2026

BCCG A Joint Venture dominates with $1.51B in CBP border wall contracts across TX and CA, fully obligated as base + options via full/open competition, signaling unmatched competitive edge in NAICS 236220. Multi-year performance (2.5-3 years to 2028) creates predictable revenue backlog for the JV. Zero outlays across all awards flag execution risks from funding delays or cost overruns under firm fixed price terms.

3 total filings
· daily

New Federal Contractors — March 23, 2026

BCCG A Joint Venture dominates with 3 DHS border barrier contracts totaling $1.51B (62% of period value), signaling strong federal priority on border infrastructure amid full/open competitions. HHS awards ($931M combined) highlight sustained demand for child services and medical staffing, though nonprofit status limits Family Endeavors equity appeal. $0 outlays on all BCCG contracts flag phased funding risks, prioritizing monitoring of execution starts in 2025.

5 total filings
· daily

Significant Contract Modifications ($10M+) — March 23, 2026

BCCG A Joint Venture dominates with $1.51B in DHS/CBP firm fixed price delivery orders for border wall systems in TX/CA (2025-2028), signaling strong revenue potential in NAICS 236220 construction amid policy-driven infrastructure. HHS contracts total $931M for child services ($714M obligated, 56% outlayed) and medical staffing ($217M obligated, 4% outlayed), offering neutral-to-bullish stability but execution risks from low disbursements. Concentration in border construction (62% of $2.44B total) warrants overweight in related equities, monitoring funding ramps.

5 total filings
· daily

Contract Deobligations Alert — March 23, 2026

BCCG A Joint Venture dominates with three DHS border wall contracts totaling $1.51B (62% of period value), signaling bullish momentum in border infrastructure construction amid full/open competitions. HHS awards to Family Endeavors ($714M, neutral nonprofit) and Spectrum Healthcare ($217M, bullish staffing) highlight services continuity but with execution risks from low outlays. Overall, $2.44B in obligations skewed to construction (NAICS 236220) offers revenue certainty through 2028 if funding materializes.

5 total filings